Drug Trial Radar · NCT06265428
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
228
Actual
Start
Jan 29, 2024
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Feb 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.
Conditions
- HER2-positive Breast Cancer
Interventions
DB-1303/BNT323Drug
Administered I.V.
T-DM1Drug
Administered I.V.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 24 months.
Locations
48 sites in 1 country. Site status is shown where the registry gives one.
015
Bengbu, Anhui, China
016
Hefei, Anhui, China
029
Hefei, Anhui, China
001
Beijing, Beijing Municipality, China
010
Beijing, Beijing Municipality, China
038
Jilin City, Changchun, China
036
Fuzhou, Fujian, China
037
Xiamen, Fujian, China
023
Guangzhou, Guangdong, China
024
Guangzhou, Guangdong, China
026
Guangzhou, Guangdong, China
028
Huizhou, Guangdong, China
017
Nanning, Guangxi, China
022
Nanning, Guangxi, China
043
Haikou, Hainan, China
045
Baoding, Hebei, China
048
Shijiazhuang, Hebei, China
020
Haerbin, Heilongjiang, China
018
Luoyang, Henan, China
006
Zhengzhou, Henan, China
005
Zhengzhou, Henan, China
011
Wuhan, Hubei, China
009
Wuhan, Hubei, China
030
Changsha, Hunan, China
027
Nanjing, Jiangsu, China
004
Nanjing, Jiangsu, China
044
Xuzhou, Jiangsu, China
014
Nanchang, Jiangxi, China
008
Changchun, Jilin, China
032
Dalian, Liaoning, China
040
Binzhou, Shandong, China
031
Jinan, Shandong, China
047
Jinan, Shandong, China
012
Linyi, Shandong, China
039
Yantai, Shandong, China
002
Shanghai, Shanghai Municipality, China
046
Shanghai, Shanghai Municipality, China
035
Taiyuan, Shanxi, China
003
Xi’an, Shanxi, China
007
Chengdu, Sichuan, China
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.